{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:00:05Z","timestamp":1777348805772,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"8","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.vaccine.2013.10.039","type":"journal-article","created":{"date-parts":[[2013,12,25]],"date-time":"2013-12-25T18:15:13Z","timestamp":1387995313000},"page":"1019-1028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: A randomized trial"],"prefix":"10.1016","volume":"32","author":[{"given":"Jennifer G.","family":"Wright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian D.","family":"Plikaytis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles E.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9007-880X","authenticated-orcid":false,"given":"Janiine","family":"Babcock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Keitel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0489-0074","authenticated-orcid":false,"given":"Hana","family":"El Sahly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Poland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6355-8752","authenticated-orcid":false,"given":"Robert M.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry L.","family":"Keyserling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera A.","family":"Semenova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarad","family":"Schiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanan","family":"Dababneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra K.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey W.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Marano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy E.","family":"Messonnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conrad P.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.10.039_bib0005","unstructured":"Anthrax Vaccine Adsorbed. United States patent US 3208909; September 28, 1965."},{"key":"10.1016\/j.vaccine.2013.10.039_bib0010","series-title":"BioThrax (anthrax vaccine adsorbed) [Vaccine package insert]","year":"2008"},{"issue":"4","key":"10.1016\/j.vaccine.2013.10.039_bib0015","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2105\/AJPH.52.4.632","article-title":"Field evaluation of a human anthrax vaccine","volume":"52","author":"Brachman","year":"1962","journal-title":"Am J Public Health Nations Health"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0020","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4049\/jimmunol.73.6.387","article-title":"Studies on immunity in anthrax. V. Immunizing activity of alum-precipitated protective antigen","volume":"73","author":"Wright","year":"1954","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0025","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/infdis\/97.2.207","article-title":"An antigen prepared in vitro effective for immunization against anthrax. III. Immunization of monkeys against anthrax","volume":"97","author":"Tresselt","year":"1955","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0030","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1128\/IAI.52.2.356-363.1986","article-title":"Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity","volume":"52","author":"Turnbull","year":"1986","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0035","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1128\/IAI.52.2.509-512.1986","article-title":"Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig","volume":"52","author":"Little","year":"1986","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0040","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1128\/IAI.52.2.454-458.1986","article-title":"Immunization studies with attenuated strains of Bacillus anthracis","volume":"52","author":"Ivins","year":"1986","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0045","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(56)91968-7","article-title":"The use of anthrax antigen to immunise man and monkey","volume":"271","author":"Darlow","year":"1956","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0050","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4049\/jimmunol.75.2.129","article-title":"Studies on immunity in anthrax. VI. Immunizing activity of protective antigen against various strains of Bacillus anthracis","volume":"75","author":"Auerbach","year":"1955","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/infdis\/115.1.59","article-title":"Studies on anthrax infections in immunized guinea pigs","volume":"115","author":"Ward","year":"1965","journal-title":"J Infect Dis"},{"issue":"Suppl. 125\u2013126","key":"10.1016\/j.vaccine.2013.10.039_bib0060","article-title":"Efficacy of a standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys","volume":"87","author":"Ivins","year":"1995","journal-title":"Salisbury Med Bull"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0065","first-page":"130","article-title":"Comparison of the efficacy of purified protective antigen and MDPH to protect non-human primates from inhalation anthrax","volume":"87","author":"Pitt","year":"1996","journal-title":"Salisbury Med Bull"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0070","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0264-410X(98)80112-6","article-title":"Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in Rhesus macaques","volume":"16","author":"Ivins","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0075","unstructured":"Cohen WA, The Secretary of Defense. Implementation of the Anthrax Vaccination Program for the Total Force. May 18, 1998. http:\/\/www.vaccines.mil\/documents\/902implementationpolicy.pdf [accessed 13.06.11]"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2013.10.039_bib0080","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0264-410X(01)00462-5","article-title":"Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans","volume":"20","author":"Pittman","year":"2002","journal-title":"Vaccine"},{"issue":"2\u20133","key":"10.1016\/j.vaccine.2013.10.039_bib0085","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0264-410X(00)00174-2","article-title":"Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans","volume":"19","author":"Pittman","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0090","series-title":"The anthrax vaccine: is it safe? Does it work?","author":"Joellenbeck","year":"2002"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0095","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jama.300.13.1532","article-title":"Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial","volume":"300","author":"Marano","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0100","unstructured":"Sun W, Food and Drug Administration. Biologics license application supplement approval letter. December 11, 2008. Available at http:\/\/www.fda.gov\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm124462.htm [accessed 13.06.11]."},{"issue":"10","key":"10.1016\/j.vaccine.2013.10.039_bib0105","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3201\/eid0810.020380","article-title":"Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen","volume":"8","author":"Quinn","year":"2002","journal-title":"Emerg Inf Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2013.10.039_bib0110","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1128\/CDLI.11.5.919-923.2004","article-title":"Mass value assignment of total and subclass immunoglobulin G in a human standard reference serum","volume":"11","author":"Semenova","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0115","unstructured":"Plikaytis BD, Holder PF, Carlone GM. ELISA for Windows user's manual, version 2.00. http:\/\/www.cdc.gov\/ncidod\/dbmd\/bimb\/ELISA.htm [accessed 14.09.11]."},{"issue":"6","key":"10.1016\/j.vaccine.2013.10.039_bib0120","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.biologicals.2010.09.001","article-title":"A two stage multilevel quality control system for serological assays in anthrax vaccine clinical trials","volume":"38","author":"Soroka","year":"2010","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0125","series-title":"Bacillus ACT05 international conference on Bacillus anthracis, B. thuringiensis and B. cereus","article-title":"A new mathematical approach to calculating dilutional titer endpoints (abstract No. P34)","author":"Soroka","year":"2005"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0130","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/1047322X.1990.10389587","article-title":"Estimation of average concentration in the presence of nondetectable values","volume":"5","author":"Hornung","year":"1990","journal-title":"Appl Occup Environ Hyg"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0135","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2008.01.007","article-title":"Standardized, mathematical model-bases and validated in vitro analysis of anthrax lethal toxin neutralization","volume":"33","author":"Li","year":"2008","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biologicals.2003.09.003","article-title":"Validation of the anthrax lethal toxin neutralization assay","volume":"32","author":"Hering","year":"2004","journal-title":"Biologicals"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2013.10.039_bib0145","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1128\/CVI.00046-13","article-title":"Characterization of the native form of anthrax lethal factor for use in the toxin neutralization assay","volume":"20","author":"Lu","year":"2013","journal-title":"Clin Vaccine Immunol"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2013.10.039_bib0150","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1128\/CVI.00267-10","article-title":"Reduction of immunogenicity of anthrax vaccines subjected to thermal stress, as measured by a toxin neutralization assay","volume":"18","author":"Castel\u00e1n-Vega","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2013.10.039_bib0155","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1128\/CVI.00003-08","article-title":"Participating laboratories. Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species","volume":"15","author":"Omland","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0160","unstructured":"\u201cWhat is a Serious Adverse Event?\u201d. US Food and Drug Administration, page last updated 23.06.11. http:\/\/www.fda.gov\/Safety\/MedWatch\/HowToReport\/ucm053087.htm [accessed 02.09.11]."},{"issue":"76","key":"10.1016\/j.vaccine.2013.10.039_bib0165","first-page":"85","article-title":"Causality assessment of adverse events following immunization","volume":"12","year":"2011","journal-title":"Wkly Epidemiol Record"},{"issue":"6","key":"10.1016\/j.vaccine.2013.10.039_bib0170","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/BF01068419","article-title":"A comparison of the two onesided tests procedure and the power approach for assessing the equivalence of average bioavailability","volume":"15","author":"Schuirmann","year":"1987","journal-title":"J Pharmacokinet Biopharm"},{"issue":"2","key":"10.1016\/j.vaccine.2013.10.039_bib0175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF01063556","article-title":"Power of the two one-sided tests procedure in bioequivalence","volume":"18","author":"Phillips","year":"1990","journal-title":"J Pharmacokinet Biopharm"},{"issue":"12","key":"10.1016\/j.vaccine.2013.10.039_bib0180","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/sim.4780091208","article-title":"Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or nonunity relative risk","volume":"9","author":"Farrington","year":"1990","journal-title":"Stat Med"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2013.10.039_bib0185","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/CVI.00099-13","article-title":"Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis","volume":"20","author":"Ionin","year":"2013","journal-title":"Clin Vaccine Immunol"},{"issue":"January (4)","key":"10.1016\/j.vaccine.2013.10.039_bib0190","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.vaccine.2009.10.111","article-title":"Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in Rhesus macaques","volume":"28","author":"Livingston","year":"2010","journal-title":"Vaccine"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2013.10.039_bib0195","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1128\/IAI.72.6.3471-3477.2004","article-title":"Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine","volume":"72","author":"Marcus","year":"2004","journal-title":"Infect Immun"},{"issue":"RR-6","key":"10.1016\/j.vaccine.2013.10.039_bib0200","article-title":"Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"CDC","year":"2009","journal-title":"Morb Mort Wkly Rep"},{"issue":"11","key":"10.1016\/j.vaccine.2013.10.039_bib0205","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1128\/CVI.00324-12","article-title":"A three dose intramuscular schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long term protection against inhalation anthrax in Rhesus macaques","volume":"19","author":"Quinn","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0210","unstructured":"Madigan D. 8 November 2007. Anthrax vaccines: bridging correlates of protection in animals to immunogenicity in humans. Washington, DC: Center for Biologics Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/NewsEvents\/WorkshopsMeetingsConferences\/TranscriptsMinutes\/UCM054424.pdf [accessed 06.07.12]."},{"issue":"May (Suppl. 3)","key":"10.1016\/j.vaccine.2013.10.039_bib0215","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0264-410X(02)00163-9","article-title":"Workshop summary. Aluminum in vaccines","volume":"20","author":"Eickhoff","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0220","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4161\/hv.3.5.4459","article-title":"Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults","volume":"3","author":"Campbell","year":"2007","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.vaccine.2013.10.039_bib0225","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/j.vaccine.2006.05.044","article-title":"Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial","volume":"24","author":"Gorse","year":"2006","journal-title":"Vaccine"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2013.10.039_bib0230","first-page":"e1384P","article-title":"Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults","volume":"5","author":"Brown","year":"2010","journal-title":"PLoS One"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13014151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13014151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T08:44:50Z","timestamp":1688892290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13014151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0264410X13014151"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.10.039","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: A randomized trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.10.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}